Japan’s cost-effectiveness assessment (CEA) panel has approved a revised handling policy for the CEA system for FY2026, with the health…
HOME > June 11, 2024
Daily News
June 11, 2024
- Takeda Rebuts ISS’ Advice to Vote against Re-Election of CEO Weber
June 11, 2024
- MHLW to Issue Nitrosamine Risk Communication Guidance by June-End; Draft Now Ready
June 11, 2024
- Industry’s Ability to Communicate Being Put to Test as Views on Off-Year Price Cuts Change
June 11, 2024
- Susana Murteira Tapped as Amgen Japan President
June 11, 2024
- Govt’s New Capitalism Council Proposes Extending Scope of Mixed-Billing Scheme
June 11, 2024
- Alecensa Snags EU OK for Adjuvant Setting of ALK-Positive NSCLC
June 11, 2024
- Japan Ethical Drug Sales Up 7.3% in April: Crecon
June 11, 2024
- Keytruda Tops Japan Drug Sales Ranking for 8 Months on End: Encise
June 11, 2024
- Japan Enacts Bill to Amend Regenerative Medicine Safety Act, Clinical Trial Act
June 11, 2024
- Takeda Rolls Out Obizur for Acquired Hemophilia A in Japan
June 11, 2024
- Kissei Grants Korean Rights for GnRH Antagonist Linzagolix to JW
June 11, 2024
- Leqembi’s Monthly IV Dosing Accepted for FDA Review: Eisai
June 11, 2024
- Moderna Files Updated Spikevax for JN.1 Strain in Japan
June 11, 2024
Japan is finally launching technical discussions on its cost-effectiveness assessment (CEA) system. A health ministry-funded research group is set to…
In the complex landscape of the Japanese pharmaceutical market, the “status quo” is often the safest harbor. But for leaders like Kennet Brysting, former president of Gilead Japan, the status quo is the most dangerous place to stay.Innovation in Japan…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…